ArticleSubstance abuse treatment, prevention, and policy2026
Single state agency licensure requirements for substance use disorder treatment programs in the United States: results of a national survey.
Article in Substance abuse treatment, prevention, and policy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSubstance use disorder (SUD) remains a critical public health crisis in the United States, with high prevalence and overdose mortality rates. Despite the availability of effective treatments, including medications that significantly reduce overdose risk, fewer than 20% of Americans with active SUD receive treatment annually. Single State Agencies (SSAs), which oversee federal funding and regulate SUD treatment programs, hold significant authority to impose licensure and reporting requirements intended to promote treatment quality.
methodsThis study presents findings from a national survey of SSAs across 50 states and the District of Columbia (94% response rate) conducted between 2020 and 2021, examining their roles in licensing SUD programs and setting requirements to promote evidence-based clinical practice.
resultsResults reveal that 58.3% of SSAs were responsible for licensing SUD treatment programs, with most requiring reporting primarily from publicly funded programs rather than all licensed providers. Staffing and clinical practice requirements varied substantially across treatment settings: opioid treatment programs and inpatient withdrawal management services were most frequently subject to medical staffing and supervision mandates, while outpatient programs were less regulated in these respects. Few SSAs required minimum staffing ratios or mandated medical professionals on staff in outpatient settings, limiting access to medication-based treatments. While patient placement criteria and clinical assessments were commonly required, clinical supervision requirements were inconsistent, and data reporting was often limited. Across treatment settings, treatment and aftercare/discharge planning were commonly required.
conclusionsThe study findings indicate that agency requirements in many states allow for SUD treatment practices and staffing arrangements that are inconsistent with evidence-based care. Balancing quality improvements with maintaining access to care may necessitate additional resources and technical support for treatment programs to meet higher standards. Enhancing licensure requirements may be a critical step toward closing persistent gaps in SUD treatment quality and expanding access to lifesaving interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.